Etirinotecan pegol (trade name Onzeald) is a drug developed by Nektar Therapeutics for the treatment of certain kinds of breast cancer with brain metastases. The European Medicines Agency refused to grant it a marketing authorisation in 2017.[2]
Clinical data | |
---|---|
Trade names | Onzeald |
Other names | NKTR-102 |
Routes of administration | Intravenous infusion |
ATC code | |
Pharmacokinetic data | |
Protein binding | none |
Metabolites | irinotecan and its metabolites |
Elimination half-life | 38 days |
Excretion | mostly via kidneys |
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C153H176N20O36[C8H16O4]n (n≈113) |
Molar mass | 20,900–24,900 g/mol[1] |
It works as a topoisomerase I inhibitor.[3] Chemically, it consists of four units of irinotecan (a topoisomerase I inhibitor in use since the late 1990s[4]) linked by carboxymethyl glycine and polyethylene glycol (PEG) chains to a central pentaerythritol ether, resulting in a much longer biological half-life (38 days) than that of irinotecan. It is formulated as a dihydrochloride and with 1.2 units of trifluoroacetate.[1]
This antineoplasticorimmunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |